Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Intensiteit behandeling endeldarmkanker afgenomen
feb 2024 | Chirurgie, Endoscopie, Maag-darm-leveroncologie, Radiotherapie